Drugs / Tribenoside
Tribenoside
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 0 | NCT04017845 Comparator | Apr 2015 → May 2017 | adenomatous colon polyp, colorectal cancer | Lewai Sharki Abdulaziz, MSc PhD | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tribenoside | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04017845 ↗ |
| Known as | 21401-BA | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301681 ↗ |
| Known as | Hemocuron | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301681 ↗ |
| Known as | Tribenosido | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301681 ↗ |
| Modality | Small molecule | — CHEMBL3301681 ↗ |
| Route | Rectal | “Treatment of hemorrhoids was initiated with tribenoside 400 mg + lidocaine 40 mg suppositories, once daily for up to 2 weeks.” NCT04017845 ↗ |